Skip to main content
padlock icon - secure page this page is secure

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double‐blind, placebo‐controlled phase 3 trial

Buy Article:

$52.00 + tax (Refund Policy)

Abstract

This study investigated the efficacy and safety of masitinib, a selective tyrosine kinase inhibitor capable of downregulating mast cell functions, for treatment of canine atopic dermatitis (CAD). Dogs with confirmed CAD received masitinib at 12.5 mg/kg/day (n = 202) or control (n = 104) for 12 weeks. A reduction in CAD Extent and Severity Index (CADESI‐02) score of ≥50% at week 12 was observed in 61% of masitinib‐treated dogs versus 35% of control dogs (P <0.001), according to the modified intent‐to‐treat population. For dogs resistant to ciclosporin and/or corticosteroids (60% of the study population), CADESI‐02 response rates were 60 versus 31%, respectively (P =0.004). The mean reduction in pruritus score of severely pruritic dogs was 46 versus 29%, respectively (P =0.045). Furthermore, 65% of owners with severely pruritic dogs assessed masitinib efficacy as good/excellent versus 35% control (P =0.05). Overall, 63% of investigators assessed masitinib efficacy as good/excellent versus 35% control (P <0.001). Premature discontinuations from the modified intent‐to‐treat population (28.2% masitinib versus 26.0% control) were mainly due to adverse events (13.4 versus 4.8%, respectively) or lack of efficacy (12.4 versus 18.3%, respectively). In total, 13.2% dogs presented with severe adverse events (16.0% masitinib versus 7.7% control). Masitinib showed a risk of reversible protein loss, although regular surveillance of blood albumin and proteinuria allowed for discontinuation of treatment while the dog was still clinically asymptomatic. Masitinib proved to be an effective and mostly well‐tolerated treatment of CAD, including severe and refractory cases, with medically manageable adverse effects.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Language: English

Document Type: Research Article

Affiliations: 1: Clinique vétérinaire Europa, Boulogne Billancourt, France 2: Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA 3: Clinique vétérinaire, Cesson-Sévigné, France 4: Unité de Parasitologie, Ecole Nationale Vétérinaire d’Alfort, Unité Mixte de Recherche BIPAR, UMR AFSSA-ENVA-UPEC-LERPAZ, Maisons-Alfort, France 5: Cabinet vétérinaire, Spa, Belgium 6: Clinique vétérinaire, Bruxelles, Belgium 7: Clinique vétérinaire, Choisy-Le-Roy, France 8: Facultatea de Medicina Veterinara, Bucarest, Roumania 9: University of Illinois, Urbana-Champaign, IL, USA 10: Animal Dermatology and Allergy, Sacramento, CA, USA 11: Southwest Veterinary Dermatology, Houston, TX, USA 12: Veterinary Skin and Allergy Specialists, Englewood, CO, USA 13: Clinique vétérinaire des Alizés, Abymes, France 14: AB Science, Paris, France

Publication date: December 1, 2011

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more